C13 Ovarian Cancer

• Research type

  Research Study

• Full title

  Hyperpolarized [1–13C]pyruvate and magnetic resonance imaging (MRI) in ovarian cancer – a physiological study

• IRAS ID

  261335

• Contact name

  Evis Sala

• Contact email

  es220@cam.ac.uk

• Sponsor organisation

  Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge

• Duration of Study in the UK

  4 years, 11 months, 30 days

• Research summary

  Hyperpolarized [1–13C]pyruvate and magnetic resonance imaging (MRI) in ovarian cancer

  The purpose of this study is to gain a better understanding of ovarian tumours which we hope will help patients in the future. Current evidence suggests that there is a build-up of a chemical called ‘lactate’ within tumours, including ovarian tumours, and that this chemical should be visible with a new imaging technique we are using known as ‘Hyperpolarised Carbon MRI’. This study will include patients with high grade serous ovarian cancer (HGSOC) before start of treatment as well as during treatment and after surgery. The examinations will be carried out at the Cambridge University Hospital.
  Data acquired during this study will be used to improve future MRI scanning and information about lactate levels may help to predict treatment outcomes and enable doctors to decide the best course of treatment for each individual in the future.

• REC name

  East of England - Cambridge Central Research Ethics Committee

• REC reference

  19/EE/0230

• Date of REC Opinion

  15 Aug 2019

• REC opinion

  Favourable Opinion